Research Article
Novel Target Study to Cure Cardiovascular Disease regarding Proprotein Converse Subtilisin/Kexin Type 9
Table 2
ADME (adsorption, distribution, metabolism, and excretion) properties of compounds.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
aAqueous solubility level: 0 (extremely low); 1 (very low, but possible); 2 (low); and 3 (good); bblood-brain barrier level: 0 (very high penetrant); 1 (high); 2 (medium); 3 (low); and 4 (undefined); ccytochrome P450 2D6 level: 0 (noninhibitor) and 1 (inhibitor); dhepatotoxicity: 0 (nontoxic) and 1 (toxic); ehuman intestinal absorption level: 0 (good); 1 (moderate); 2 (poor); and 3 (very poor); fplasma protein binding: 0 (binding is <90%); 1 (binding is >90%); and 2 (binding is >95%). |